Keyphrases
Toll-like Receptor 7 (TLR7)
100%
Cancer Vaccine
100%
Sunitinib
100%
Nanovaccine
100%
Anticancer Activity
100%
Programmed Death ligand-1 Blockade
100%
Nanoparticles
50%
CD8+ T Cells
50%
Anti-programmed death-1 Monoclonal Antibody
50%
Programmed Death-ligand 1 (PD-L1)
33%
Tumor Microenvironment
33%
Antitumor Efficacy
33%
Myeloid-derived Suppressor Cells
33%
Therapeutic Efficacy
33%
Antibody Treatment
33%
Antigen-specific CD8+ T Cells
33%
Tumor
16%
Regulatory T Cells
16%
Tyrosine Kinase Inhibitor
16%
Toll-like
16%
Inhibitory Signaling
16%
Tumor Antigen
16%
CD8+ T Cell Response
16%
Treg
16%
T Cell Activation
16%
T-cell Mediated
16%
Receptor Agonist
16%
Variable Response
16%
Murine Tumor Model
16%
Tumor Rejection
16%
Immune Escape
16%
B16F10
16%
M2 Macrophages
16%
CD8+ T Cell Exhaustion
16%
Anti-programmed Death 1
16%
Immune Suppressive Cells
16%
MB49
16%
Immune-suppressive
16%
Resistance Development
16%
Tumor Microenvironment Modulation
16%
Medicine and Dentistry
Toll Like Receptor 7
100%
Sunitinib
100%
Programmed Death 1 Ligand 1
100%
Nanovaccine
100%
Cytotoxic T-Cell
85%
Tumor Vaccine
85%
Tumor Microenvironment
42%
Nanoparticle
42%
Combination Therapy
28%
Antigen Specificity
28%
Malignant Neoplasm
14%
T-Cell Response
14%
Neoplasm
14%
Tumor Model
14%
Regulatory T Cell
14%
T Cell Activation
14%
Tyrosine-Kinase Inhibitor
14%
Tumor Antigen
14%
Toll Like Receptor Agonist
14%
Tumor Rejection
14%
M2 Macrophages
14%
Pharmacology, Toxicology and Pharmaceutical Science
Toll Like Receptor 7
100%
Programmed Death 1 Ligand 1
100%
Sunitinib
100%
Nanovaccine
100%
CD8 Antigen
85%
Tumor Vaccine
85%
Nanoparticle
42%
Tumor Microenvironment
42%
Neoplasm
28%
Combination Therapy
28%
Preclinical Study
14%
Malignant Neoplasm
14%
Tumor Model
14%
Protein Tyrosine Kinase Inhibitor
14%
Toll Like Receptor Agonist
14%
Tumor Antigen
14%
Immunology and Microbiology
Agonist
100%
TLR7
100%
Programmed Death 1 Ligand 1
100%
Sunitinib
100%
Cytotoxic T-Cell
85%
Tumor Vaccine
85%
Regulatory T Cell
28%
Antigen Specificity
28%
Myeloid
28%
T Cell Activation
14%
Immune Escape
14%
Preclinical Study
14%
Tumor Rejection
14%
Tumor Antigen
14%
M2 Macrophages
14%
Tyrosine
14%
Toll-Like Receptor
14%